Bayer AG will not pursue development of one its significant cancer therapies, Aliqopa (copanlisib), in diffuse large B-cell lymphoma (DLBCL) despite completing Phase II trials, the company noted in its first quarter financial report for 2018.
Included in Bayer’s Q1 2018 report was a list of “important” pipeline assets currently in Phase II and Phase III trials (see table below).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?